Rapid Autopsy Protocol for Patients With Small Cell Lung Cancer
This is pilot study to establish a rapid autopsy program in Small Cell Lung Cancer (SCLC) at the Indiana University Simon Comprehensive Cancer Center and outline the components necessary for tumor tissue collection.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Jul 14, 2026 · Source: ClinicalTrials.gov
The study is currently accepting participants.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Indiana University
- Interventions being studied
- Procedure: Biospecimen Collection
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
1. ≥ 18 years old at the time of informed consent 2. Written informed consent and HIPAA authorization for release of personal health information. 3. Active SCLC diagnosis.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis, Indiana
- Roudebush VA Medical CenterIndianapolis, Indiana
- Sidney and Lois Eskenazi HospitalIndianapolis, Indiana
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 14, 2026. Always confirm current availability with the study team.